Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple MyelomaBruno Paiva, Noemí Puig, María‐Teresa Cedena et al.|Journal of Clinical Oncology|2019Cited by 279
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenanceMaría‐Victoria Mateos, Jesús F. San Miguel, Norma C. Gutiérrez et al.|Blood|2011Cited by 58
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical TrialJuan Manuel Rosa-Rosa, Joaquín Martínez‐López, Natalia Buenache et al.|Cancers|2022Cited by 15